Anti-CDH19/CD3 HLE BiTE

N/A

Report date: 2026/03/19 16:58:15

Base Information

Drug NameAnti-CDH19/CD3 HLE BiTE

Drug Alias Nameanti-CD3/anti-cadherin 19 bispecific T-cell engager HLE-BiTE (Amgen)CDH19 BiTEanti-CD3/anti-CDH19 BiTE (Amgen)AMG-CDH19X

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionProtocadherin-19 modulatorsT cell surface glycoprotein CD3 modulators

TargetsProtocadherin-19T cell surface glycoprotein CD3

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc

Inactive CompaniesN/A

Active IndicationsMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A